Abstract 234P
Background
The literature reports that a minority of women with epithelial ovarian cancer (EOC) are referred for germline BRCA testing despite implications for treatment and cancer prevention. Mainstream testing is BRCA testing undertaken by the Medical Oncology service, rather than clinical genetics; and it was introduced at Auckland Hospital in 2017. This study assessed whether the implementation of mainstreaming increased the uptake and timeliness of BRCA testing in a multi-cultural tertiary centre.
Methods
A retrospective analysis of women with high grade non-mucinous EOC attending Medical Oncology clinic was performed prior to and after the introduction of mainstream testing. Eligibility for BRCA testing included those with the above diagnosis ≤ 70 years (tested by Medical Oncology after mainstreaming introduced) and patients > 70 years with a personal and/or relevant family history (tested by genetics). The primary outcome was the proportion of eligible patients who underwent BRCA testing. A secondary outcome was the time to the availability of the BRCA test result.
Results
The proportion of eligible women tested for germline BRCA mutations significantly increased (Table). The improvement was due to increased testing via mainstreaming; there was no change in the proportion of women tested through the Genetics service. Efficiency of testing also improved; the median time from Genetics referral to an available BRCA result was 146 days (range 37 to 1599 days) and from Medical Oncology assessment to BRCA test result 64 days (range 34 to 471 days) before and after mainstreaming respectively. Overall, 14.9% of women had germline BRCA 1 or 2 mutations.
Table: 234P
Pre- mainstreaming | Post- mainstreaming | P value | |
---|---|---|---|
Eligible for mainstreaming* | 108/177 (61.0%) | 37/40 (92.5%) | 0.0001 |
>70 years + personal/ family history** | 10/15 (66.7%) | 7/9 (77.8%) | 0.6687 |
Overall | 118/192 (61.5%) | 44/49 (89.8%) | 0.0001 |
Pre-mainstreaming, patients tested by Genetics; post-mainstreaming, tested in Medical Oncology clinic.
**Tested by Genetics.
Conclusions
Mainstream testing for germline BRCA mutations improved quality – access and timeliness – for women with EOC. Efficiency of testing will have important therapeutic implications.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Auckland District Health Board.
Funding
Auckland District Health Board.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract